Home  »  Finance   »  Analysts Update Their Estimates For 10x Genomics I...

Analysts Update Their Estimates For 10x Genomics Inc.

10x Genomics Inc. (NASDAQ:TXG) concluded the trading at $30.23 on Wednesday, September 21 with a fall of -5.47% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $31.98 and 5Y monthly beta was reading 1.86 with its price kept floating in the range of $30.23 and $32.79 on the day. Considering stock’s 52-week price range provides that TXG hit a high price of $187.85 and saw its price falling to a low level of $29.17 during that period. Over a period of past 1-month, stock came subtracting -13.65% in its value.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored

With its current market valuation of $3.76 billion, 10x Genomics Inc. is set to declare its quarterly results on Feb 15, 2022 – Feb 21, 2022. Analysts are in estimates of -$0.39 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.22 for 2022 with estimates of that growing to -$0.48 in next year. These estimates are suggesting current year growth of -130.20% for EPS and 60.70% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $117.19 million. They suggested that in the process company could generate revenue of as low as $114.15 million which could climb up to $125 million to hit a high. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $571.06 million in 2022, which will be 16.40% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review TXG stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

Digging deeper we become aware of the PEG ratio of the TXG stock which is currently positioned at 0. It further provides that stock’s current price level is -10.34% away from its 20-day simple moving average and is -20.62% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 37.28 while volatility remained at 7.68% over the past week which changes to 6.65% when measuring it over the past month. Average true range or ATR is currently at 2.45.

In comparing 10x Genomics Inc. (TXG)’s stock with other industry players reveals that stock’s current price change of -5.47% and that of -81.22% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price fall by -2.50% in the last trading and went through a decrease of -5.74% in past 12-month trading. Industry’s another major player Enerplus Corporation (ERF) has fall -3.36% down in previous session, but over the past year has faced a rise of 138.22%, while Pacific Biosciences of California Inc. (PACB) was also down -1.89% however its price remained floating in the red at -79.13% over the same period. 10x Genomics Inc. has a P/E ratio of 0 against that of Becton Dickinson and Company’s 44.98 while Enerplus Corporation is showing 6.82 for the same. On the other hand, the S&P 500 Index was down -1.71% in the last trading session while the Dow Jones Industrial closed the session lower at -1.70%.

Having a second look at 10x Genomics Inc. (NASDAQ:TXG) provides that stock’s average daily trading volume for 3 months was 1.42 million, while it jumped to 1.22 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 113.58 million.

The figures also indicate that as of Jul 14, 2022, number of stock’s short shares was 5.97 million which implies a short ratio of 3.49. This shows down a 5.26% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short improved as it was 6.89 million in the previous month. Subtraction of -79.71% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]